Podcasts about OS

A year of funded FreeBSD, ZFS Performance Tuning – Optimizing for your Workload, Three Ways to Try FreeBSD in Under Five Minutes, FFS optimizations with dirhash, j2k25 hackathon report from kn@, NetBSD welcomes Google Summer of Code contributors, and more NOTES This episode of BSDNow is brought to you by Tarsnap (https://www.tarsnap.com/bsdnow) and the BSDNow Patreon (https://www.patreon.com/bsdnow) Headlines A year of funded FreeBSD (https://www.daemonology.net/blog/2025-06-06-A-year-of-funded-FreeBSD.html) ZFS Performance Tuning – Optimizing for your Workload (https://klarasystems.com/articles/zfs-performance-tuning-optimizing-for-your-workload/) News Roundup Three Ways to Try FreeBSD in Under Five Minutes (https://freebsdfoundation.org/blog/three-ways-to-try-freebsd-in-under-five-minutes/) FFS optimizations with dirhash (https://rsadowski.de/posts/2025/ffs-optimizations-dirhash/) j2k25 hackathon report from kn@: installer, low battery, and more (https://undeadly.org/cgi?action=article;sid=20250616082212) NetBSD welcomes Google Summer of Code contributors (https://blog.netbsd.org/tnf/entry/gsoc2025_welcome_contributors) Tarsnap This weeks episode of BSDNow was sponsored by our friends at Tarsnap, the only secure online backup you can trust your data to. Even paranoids need backups. Feedback/Questions Send questions, comments, show ideas/topics, or stories you want mentioned on the show to feedback@bsdnow.tv (mailto:feedback@bsdnow.tv) Join us and other BSD Fans in our BSD Now Telegram channel (https://t.me/bsdnow)

O Alzheimer fez a Cláudia se aproximar da mãe, com ela tinha uma relação muito complexa. Cláudia passou 63 anos sob o mesmo teto que a mãe, unidas quase só pela rotina. A infância foi dura: a mãe, criada num quintal onde havia até uma “cela” de castigo, reproduziu a rigidez que aprendera. Quando o irmão preferido morreu, aos 14 anos, Cláudia carregou a sensação de ser a filha “errada”. Mesmo adulta, não saiu de casa: o cuidado permaneceu, mas o afeto nunca chegou por parte da sua mãe.Já com a mãe idosa e uma relação distante, vieram os pequenos esquecimentos: despedidas repetidas, panelas queimadas, noites em claro. Quando foram procurar um médico, o diagnóstico de Alzheimer fez Cláudia perguntar se a mãe acabaria esquecendo dela. Ali nasceu a urgência de reconstruir um vínculo que nunca existiu.A doença levou a mãe de volta a um tempo em que procurava a “Cláudia criança”. Para acalmá-la, a filha aprendeu a linguagem do toque e da música: mãos no rosto, olhos nos olhos, canções antigas. Foi nesse espaço que, pela primeira vez, Cláudia ouviu “eu te amo” de quem nunca soube demonstrar amor. Secar louça dançando virou um ritual para as duas, e esses momentos foram parar na internet, no canal “O Bom do Alzheimer”, porque foi a partir da doença que veio a leveza entre elas.Hoje, aos 90, a mãe fala pouco e depende de tudo. Os banhos antes cheios de gritos agora acontecem em silêncio, não por compreensão, mas pela progressão do Alzheimer. Cláudia encara cada dia como um ensaio para a despedida lenta, sem perder a ternura que finalmente brotou daquela relação entre mãe e filha.Nas palestras e no livro que escreveu, ela repete o alerta: mudanças bruscas de comportamento não são “coisa da idade”. O Brasil esta envelhecendo, e reconhecer cedo sinais como esquecimento constante faz diferença. Foi assim que Cláudia transformou um diagnóstico em oportunidade de amor, mesmo que tardio. Aproveitando, o Alzheimer não trouxe nenhum castigo divino; mas trouxe a chance de, antes do esquecimento completo, lembrar que ainda era possível dizer: mãe, eu estou aqui.O livro da Cláudia "O Bom do Alzheimer" você compra aqui: https://amzn.to/3G9scPgFoto da capa: Estadão

Dr. Michael Sapiro is a clinical psychologist, ordained Zen Buddhist monk, and the author of Truth Medicine, a powerful new book exploring the healing potential of psychedelic-assisted therapy, presence, and inner transformation.15 Daily Steps to Lose Weight and Prevent Disease PDF: https://bit.ly/46XTn8f - Get my FREE eBook now!Subscribe to The Genius Life on YouTube! - http://youtube.com/maxlugavereWatch my new documentary Little Empty Boxes - http://littleemptyboxes.comThis episode is proudly sponsored by:Shopify makes it easy to accept payments, manage orders, and build relationships with customers (cha-ching!). Get everything you need to sell in person and online at http://shopify.com/genius and get a one-dollar-per-month trial period!OneSkin is a skincare company for minimalists utilizing their revolutionary OS-01 peptide which can reverse signs of skin aging according to their research. Visit http://oneskin.co/max and use code MAX for 15% off.Momentous is a new supplement brand that holds its products to rigorous quality and purity standards set by the NFL and NBA. I use their creatine and protein regularly. Head to livemomentous.com/genius or use code GENIUS for 35% off your first subscription.Pique makes quadruple toxin-screened, cold extracted, and uber-delicious matcha for an all-day energy boost without the jitters! Head to http://piquelife.com/genius for up to 15% off.Fatty15 provides C15:0, a naturally occurring fatty acid found in full-fat dairy that may support cellular health and longevity—get 15% off at http://fatty15.com/MAX with code MAX!

Por que eu não estou melhorando, mesmo fazendo terapia?Por que tenho a sensação de estar estagnado(a), de andar em círculos, às vezes até de estar pior do que antes?E se o problema não fosse você… mas simplesmente uma parte normal do processo?Neste episódio, falamos sem filtro sobre as dúvidas, os bloqueios e os silêncios que podem surgir durante a terapia. Também falamos sobre o que a terapia pode (ou não pode) fazer por nós.Você não está sozinho(a) ao sentir frustração, desânimo ou até vergonha em relação ao seu próprio ritmo. E se reaprendêssemos a confiar no caminho, mesmo quando ele parece nebuloso?Um episódio para todos que já pensaram:

Think you know how to use sunscreen? Think again! In this episode of Spa Skin and Beauty, I break down the most common sunscreen mistakes — from not using enough (did you know most people use only half the needed amount?) to forgetting those easy-to-miss spots like ears and lips. Plus, find out why your makeup with SPF isn't cutting it, the best way to measure your sunscreen, and how to use UV apps to protect your skin smarter. If you want to keep your skin glowing and protected, you can't miss this! Tune in now and get ready to upgrade your sun protection game! XX, Lindsey Next Steps: Book a ONE on ONE Skincare Routine coaching call with me to get you Radiant skin!  LISTEN TO EXCLUSIVE PODCAST CONTENT and Download our FREE Esthetician led Skincare app: Apple IOS  Here OR Google Play Here Download my Free 7 Day Skincare Guide: Here If you liked this episode, you will also like this one : Discover Your Skin type: HERE Favorite Skincare Products HERE Pipette Minderal SPFEWG Verified!! BABO BOTANICALS | Tinted Face Mineral Sunscreen Stick SPF 50 - Fragrance Free The Skinny Confidential Caffeinated Mineral Sunscreen ONESKIN | Os-01 Shield Protect + Repair SPF 30+ Mychelle Light 3-In-1 Super Serum Beauty By Earth Self Tanner - Usa Made With Natural & Organic Ingredients Babo Botanicals Super Shield SPF 50 Stick Sunscreen - 70% Organic Ingredients Babo Botanicals Sheer Zinc Continuous Sunscreen Spray SPF30 ONESKIN | Os-01 Shield Protect + Repair SPF 30+ ONESKIN | Triple Power Os-01 Body SPF Babo Botanicals Daily Sheer Mineral Sunscreen Fluid SPF50 - Natural Zinc Oxide  KORA ORGANICS | Silky Sun Drops Organic Sunscreen Serum With SPF 30 Babo Botanicals Daily Sheer Tinted Mineral Sunscreen Fluid SPF50 - Natural Zinc Oxide Ava Isa Sun-È-Serum Drops SPF 35  Sun Cream SPF 30 Sun Stick SPF 25 Sun Lip Balm SPF 15 Os-01 Lip SPF Connect with me:  @lindseyrholder and @spaskinandbeauty  Leave a review and get instant access to my  48 Hour Skincare Makeover Guide: HERE Listen to related episodes: Sunscreen Stars of Summer 2025: Esthetician-Approved SPF Picks The Morning Skin Protocol That Changes Everything (From Lymph to Light) Skincare in a Hurry: Live Coaching a Busy Mom with Oily Skin & Dark Circles  

Guest: Sarah Aoun, Privacy Engineer, Google Topic: You have had a fascinating career since we [Tim] graduated from college together – you mentioned before we met that you've consulted with a literal world leader on his personal digital security footprint. Maybe tell us how you got into this field of helping organizations treat sensitive information securely and how that led to helping keep targeted individuals secure?  You also work as a privacy engineer on Fuschia, Google's new operating system kernel. How did you go from human rights and privacy to that?  What are the key privacy considerations when designing an operating system for “ambient computing”? How do you design privacy into something like that? More importantly, not only “how do you do it”, but how do you convince people that you did do it? When we talk about "higher risk" individuals, the definition can be broad. How can an average person or someone working in a seemingly less sensitive role better assess if they might be a higher-risk target? What are the subtle indicators? Thinking about the advice you give for personal security beyond passwords and multi-factor auth, how much of effective personal digital hygiene comes down to behavioral changes versus purely technical solutions? Given your deep understanding of both individual security needs and large-scale OS design, what's one thing you wish developers building cloud services or applications would fundamentally prioritize about user privacy? Resources: Google privacy controls Advanced protection program

✅CUPOM 15-JOELJOTA: https://bit.ly/d2csummit-jjSegunda-feira não é só mais um dia. É o dia em que você mostra pra você mesmo quem comanda a sua vida.

Uma ameaça de morte leva Guedes (Rafael Medrado), o melhor amigo de Zé (Tiago Teotónio Pereira) a revelar um segredo escondido. E o inspetor da PJ que investiga o caso (Paulo Calatré) recebe um pedido de ajuda inesperado. O “Zé faz 25” é um podcast de ficção para ouvir em oito episódios. Uma coprodução do Observador com a Coyote Vadio, que conta ainda no elenco com Sara Matos, Madalena Almeida, Cristovão Campos, Vicente Wallenstein, José Raposo e Carla Maciel. Pode ouvir semanalmente os episódios de “O Zé faz 25” na playlist própria do podcast na Apple Podcasts, Spotify, Youtube ou outras plataformas de podcast. Os assinantes standard e premium do Observador têm acesso antecipado a todos os episódios no site do Observador. See omnystudio.com/listener for privacy information.

| Os livros-textos deste episódio são: A Humanidade é Isenta de Pecado / Ciência da Oração; Para adquirir e estudar ainda mais, acesse: https://rebrand.ly/SNI_livraria;| Torne-se você também um Mantenedor das Mídias da Seicho-No-Ie! Saiba como acessando: https://rebrand.ly/mantenedor| Para encontrar a Associação Local mais próxima de você, acesse: https://rebrand.ly/onde_encontrar| Quer começar a praticar a Meditação Shinsokan, mas não sabe como? Conheça a Meditação Shinsokan guiada: https://rebrand.ly/shinsokan_7min| Acompanhe também as nossas redes sociais para mais conteúdos e novidades: https://rebrand.ly/FaceSNI (Facebook) e https://rebrand.ly/instaSNI (Instagram)

Atenção (disclaimer): Os dados aqui apresentados representam minha opinião pessoal.Não são de forma alguma indicações de compra ou venda de ativos no mercado financeiro.Os pontos de foco para o dia no mercado financeiro.Investir com SIM - Organização do canalhttps://youtu.be/rze7WP1IojkSobre doações para o canal #INVESTIRCOMSIM 18/02/25https://youtube.com/shorts/NZLctbFyx6MInvestir com SIM Shop (Lojinha)https://umapenca.com/investircomsim/

Atenção (disclaimer): Os dados aqui apresentados representam minha opinião pessoal.Não são de forma alguma indicações de compra ou venda de ativos no mercado financeiro.https://www.cnnbrasil.com.br/internacional/trump-diz-que-israel-e-ira-concordaram-com-cessar-fogo/https://www.infomoney.com.br/mundo/otan-se-reune-para-oficializar-aumento-de-gastos-militares-sob-ameaca-da-russia/https://istoedinheiro.com.br/previa-da-inflacao-de-junho-fica-em-026-e-desacelera-para-527-em-12-meseshttps://www1.folha.uol.com.br/mercado/2025/06/desemprego-recua-a-62-e-tem-menor-taxa-ate-maio-na-serie-historica.shtmlhttps://exame.com/brasil/aprovacao-de-lula-cai-para-239-e-e-a-pior-desde-o-inicio-do-governo-diz-futura/https://exame.com/brasil/tarcisio-abre-11-pontos-de-vantagem-sobre-lula-no-2o-turno-diz-pesquisa-da-futura/https://neofeed.com.br/negocios/meliuz-compra-mais-r-158-milhoes-em-bitcoin/https://www.moneytimes.com.br/meliuz-cash3-diz-que-btg-atingiu-participacao-de-1426-na-companhia-gmda/https://www.moneytimes.com.br/ca-ceab3-encerra-parceria-com-bradesco-e-paga-r-650-milhoes-por-retomada-de-servicos-financeiros-gmda/https://www.moneytimes.com.br/ambipar-retira-projecoes-relacionadas-a-potencial-parceria-com-dow-negociacoes-seguem-gmda/https://www.cnnbrasil.com.br/economia/negocios/acao-da-jbs-pode-valorizar-ate-280-na-bolsa-americana-diz-ceo/https://www.moneytimes.com.br/minerva-beef3-homologa-aumento-de-capital-e-garante-r-2-bilhoes-lmrs/https://www.moneytimes.com.br/petz-petz3-e-cobasi-petlove-tentara-ultimo-recurso-contra-a-fusao-das-concorrentes-diz-jornal-lmrs/https://valor.globo.com/empresas/noticia/2025/06/23/petlove-tentou-fusao-com-petz-e-cobasi-conversas-existiam-ate-semanas-antes-de-acordo.ghtmlhttps://br.investing.com/news/stock-market-news/azul-tenta-barrar-interrupcao-em-fornecimento-de-combustivel-1588902https://www.moneytimes.com.br/justica-dos-eua-determina-manutencao-de-fornecimento-de-combustivel-a-azul-fets/https://valor.globo.com/financas/noticia/2025/06/23/ministrio-pblico-abre-inqurito-para-apurar-supostas-irregularidades-da-xp.ghtmlhttps://www.moneytimes.com.br/guararapes-guar3-dona-da-riachuelo-quer-premiar-executivos-com-acoes-e-convoca-assembleia-entenda-o-impacto-para-os-acionistas-jcav/https://www.moneytimes.com.br/casas-bahia-bhia3-mapa-capital-assina-com-bancos-para-assumir-divida-de-r-16-bi-e-deve-adquirir-posicao-majoritaria-lmrs/Minerva (BEEF3) entra com recurso no Cade contra fusão entre BRF e Marfrighttps://exame.com/invest/mercados/minerva-beef3-entra-com-recurso-no-cade-contra-fusao-entre-brf-e-marfrig/Abertura de Mercado Mini #INVESTIRCOMSIM #BOVESPA #AÇÕES 24/06/25https://www.youtube.com/shorts/Inb3FtY1YVEThe U.S. Bombed Iran. Now What?https://podcasts.apple.com/br/podcast/the-u-s-bombed-iran-now-what/id1200361736?i=1000714164976Your bug roommateshttps://podcasts.apple.com/br/podcast/your-bug-roommates/id1554578197?i=1000714152494The Whole Hoghttps://podcasts.apple.com/br/podcast/the-whole-hog/id918896288?i=1000349424374The Good, The Bad, The Cilantrohttps://podcasts.apple.com/br/podcast/the-good-the-bad-the-cilantro/id918896288?i=1000354122815What the Israel-Iran Conflict Means for Chinahttps://podcasts.apple.com/br/podcast/what-the-israel-iran-conflict-means-for-china/id1746141911?i=1000714400852Sick of “morning” sicknesshttps://podcasts.apple.com/br/podcast/sick-of-morning-sickness/id1554578197?i=1000714472422Breaking Down the Massive Cuts to Science Fundinghttps://podcasts.apple.com/br/podcast/breaking-down-the-massive-cuts-to-science-funding/id1200361736?i=1000714642640A guerra política e fiscal declarada em Brasíliahttps://podcasts.apple.com/br/podcast/a-guerra-pol%C3%ADtica-e-fiscal-declarada-em-bras%C3%ADlia/id1477406521?i=1000714745661Who Could Rule Iran Next?https://podcasts.apple.com/br/podcast/who-could-rule-iran-next/id1258635512?i=1000714645349

Que comportamento deve o líder adoptar perante o incerto? Os nossos especialistas falam sobre o desconhecido e olham para o percurso de Andy Grove, o homem que escreveu “Só os paranóicos sobrevivem.”See omnystudio.com/listener for privacy information.

Uma ameaça de morte leva Guedes (Rafael Medrado), o melhor amigo de Zé (Tiago Teotónio Pereira) a revelar um segredo escondido. E o inspetor da PJ que investiga o caso (Paulo Calatré) recebe um pedido de ajuda inesperado. O “Zé faz 25” é um podcast de ficção para ouvir em oito episódios. Uma coprodução do Observador com a Coyote Vadio, que conta ainda no elenco com Sara Matos, Madalena Almeida, Cristovão Campos, Vicente Wallenstein, José Raposo e Carla Maciel. Pode ouvir semanalmente os episódios de “O Zé faz 25” na playlist própria do podcast na Apple Podcasts, Spotify, Youtube ou outras plataformas de podcast. Os assinantes standard e premium do Observador têm acesso antecipado a todos os episódios no site do Observador. See omnystudio.com/listener for privacy information.

No episódio de hoje, AJ Oliveira conversa com Sol Coelho e Anna Martino sobre a Bienal de 2025.Um agradecimento especial e nominal às senhoras, senhores e proletariado não-binário que apoiam este podcast:Raphael WanderleyThiago LeeAndressa Souza da Silva SchollRogério MacedoDaniel Folador RossiIan CastroAna Lúcia MeregeJulia AlvarezSuzana Vieira HerbasIan FraserDiana PassyElvis Soriano RodriguesGabriella de Jesus MoreiraRodrigo PontesDaniel de PaulaRicardo BalbinoMiguel AugustoCarolina Emy Ono LealGabriela PagnussatLINKS CITADOS NO EPISÓDIO:Comprem:SUPRASSUMA VOL3 - SONHOS (DE GRAÇA) ⁠⁠AQUI⁠⁠Itaú Cultural TEXTO AJ OLIVEIRA (DE GRAÇA) ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠AQUI⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠PROSÉRPINA, DE ANNA FAGUNDES MARTINO ⁠⁠AQUI-CANAL NO TELEGRAM (conteúdo) >>>⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Clique aqui⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠CANAL NO TELEGRAM (interação) >>>⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Clique aqui⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠-Envie seu e-mail ou eventuais dúvidas para ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠os12trabalhos@gmail.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠-Mídias Sociais:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter de Os 12 Trabalhos é @Os12Trabalhos⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter do A. J. Oliveira é @Ajota_Oliveira⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram do A. J. Oliveira é @ajota_oliveira⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

NOS HEMOS VISTO EN LA OBLIGACIÓN DE RESCATAR ESTE PROGRAMA: El 19 de Octubre de 1996 salía a la luz el tercer ejemplar de la revista Expedientes Secretos. Dicha publicación dedicaba un reportaje especial al caso JOMEL. Un expediente OVNI único, cuyos elementos lo convierten en el caso más increíble de la ufología española. Y posiblemente del mundo entero... El 15 de agosto de 1991, José María Gómez Montiel y Anabel Juarros Heras, fueron testigos de unos acontecimientos imposibles. Una nave extraordinaria y un ser ensotanado volador se materializaron frente a ellos. El humanoide encapuchado quiso aproximarse a ellos, a lo que la pareja respondió con una disparatada huida en coche como alma que lleva el diablo. Pero esto fue solo el comienzo. El expediente JOMEL guarda un grotesca mezcolanza de lo inexplicable que abarca encuentros OVNI, fenómenos paranormales, abducciones, criaturas criptozoológicas, visitantes de dormitorio, extraños seres humanoides y una increíble realidad que hoy en día parece seguir manifestándose... ¿Os atrevéis a desclasificar junto a nosotros el dossier más extraordinario del fenómeno OVNI? Agradecimientos especiales a: 🛸 José María Gómez Montiel por su amabilidad y su desinteresada disposición a prestar testimonio para colaborar con el programa. 🛸 Txelu Muñoz del podcast El Factor Enigma por sentarse frente a los micrófonos de esta posada y participar en este programa. 🛸 Isa y Alex del podcast La Última Sala por prestarnos sus voces en la dramatización del episodio y dar vida sonora a los protagonistas del caso. 🛸 Cris Etxepare por formar parte de nuestro equipo y poder contar con su voz, siempre maravillosa. 🛸 Esther de 13 Gatos por sus ilustraciones de incuestionable talento. 🛸 Javier Domínguez "Jadoga" por hacer un análisis exhaustivo y profesional desde su campo al material clave del Caso JOMEL. 🛸 Israel Gordón López del podcast Ecos de lo Remoto por facilitarnos información y prestarnos sus conclusiones personales sobre el expediente. Tema del descanso: Alerta Ovni, del grupo Los Criptozoos: https://loscriptozoos.bandcamp.com/ Programa editado por el Alquimista de la Radio, Endika Ortiz de Zárate. ¿Eres fan de La Posada Del Cuervo? Accede a todo contenido exclusivo apoyando el podcast a través del siguiente enlace: https://www.ivoox.com/support/691202 . Si disfrutas de este programa... ¡recuerda que puedes ayudarnos indicando que te ha gustado el episodio con un "me gusta" ❤️ y dejando un comentario en el foro de iVoox! Si te gusta este Podcast, te invitamos a apoyar el programa de forma totalmente voluntaria. Como gesto de agradecimiento, este caserón del misterio abrirá sus puertas con contenido exclusivo para ti. Puedes contactar con nosotros a través de las siguientes vías de contacto: Instagram: https://instagram.com/laposadadelcuervo?igshid=YmMyMTA2M2Y= Facebook: (Página) https://www.facebook.com/profile.php?id=100063581487299 (Perfil) https://www.facebook.com/LaPosadaDelCuervo Twitter: https://twitter.com/posadadelcuervo?s=21 Email: laposadadelcuervo@gmail.com Whatsapp: +34 699719337 Telegram (Grupo): https://t.me/posadacuervo Puedes apoyar el programa con una donación a través de los siguientes medios: PayPal: https://www.paypal.me/laposadadelcuervo Bizum: +34 699719337 ¡Gracias por ser huésped sonoro de La Posada Del Cuervo! Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

En este programa, como cada año y a estas alturas, Maldu y Pichu hacen sus quinielas de quienes van a ser los 53 jugadores del roster elegidos para disputar la próxima temporada. Con quien estáis más de acuerdo? Os falta algún jugador no mencionado por ninguno de los 2? Es un roster para ilusionarse de cara a competir por la ansiada SB?Muchas gracias a tod@s l@s oyentes y Go Lions!

*** VIDEO EN NUESTRO CANAL DE YOUTUBE **** https://youtube.com/live/NuRNTuiZInM +++++ Hazte con nuestras camisetas en https://www.bhmshop.app +++++ #historia #historiamilitar #antigüedad Gracias a Benjamín Collado, autor de “Guerreros de Iberia” ** https://amzn.to/3hCSQQC *, conoceremos las monomachias, "los combates singulares" de la Antigüedad. Os invito a leer los libros de Benjamín Collado * https://amzn.to/3TTCBDa * y ver los programas "LOS IBEROS, UNAS SOCIEDADES GUERRERAS" -- https://youtu.be/QR0WcAA9_KE -- y "LOS CELTIBEROS EN GUERRA, armas, tácticas y fortificaciones " -- https://youtube.com/live/ZsFPLd6FN3M *************************************************** COMPRA EN AMAZON CON EL ENLACE DE BHM Y AYUDANOS ************** https://amzn.to/3ZXUGQl ************* Si queréis apoyar a Bellumartis Historia Militar e invitarnos a un café o u una cerveza virtual por nuestro trabajo, podéis visitar nuestro PATREON https://www.patreon.com/bellumartis o en PAYPALhttps://www.paypal.me/bellumartis o en BIZUM 656/778/825

Agradece a este podcast tantas horas de entretenimiento y disfruta de episodios exclusivos como éste. ¡Apóyale en iVoox! Acceso anticipado para Fans - *** VIDEO EN NUESTRO CANAL DE YOUTUBE **** https://youtube.com/live/oJbkQgogzkU +++++ Hazte con nuestras camisetas en https://www.bhmshop.app +++++ #historia #historiadeespaña El 13 de septiembre de 1974 la madrileña "Cafetería Rolando" pasaría a la historia de España por ser el primer atentado indiscriminado de E.T.A. como nos cuenta Gaizka Fernández Soldevilla, autor del libro "Dinamita, tuercas y mentiras" ** https://amzn.to/3E42omc ** . Os invito a ver los progamas anteriores sobre el terrorismo en España: -EL ORIGEN DE E.T.A. https://youtube.com/live/4gw-P65sSGg - E.T.A. CONTRA LA JOVEN DEMOCRACIA ESPAÑOLA https://youtube.com/live/0EjwAhqvf9c COMPRA EN AMAZON CON EL ENLACE DE BHM Y AYUDANOS ************** https://amzn.to/3ZXUGQl ************* Si queréis apoyar a Bellumartis Historia Militar e invitarnos a un café o u una cerveza virtual por nuestro trabajo, podéis visitar nuestro PATREON https://www.patreon.com/bellumartis o en PAYPALhttps://www.paypal.me/bellumartis o en BIZUM 656/778/825 Escucha este episodio completo y accede a todo el contenido exclusivo de BELLUMARTIS PODCAST. Descubre antes que nadie los nuevos episodios, y participa en la comunidad exclusiva de oyentes en https://go.ivoox.com/sq/618669

Leitura Bíblica Do Dia: MARCOS 2:13-17  Plano De Leitura Anual: JÓ 14–16; ATOS 9:22-43  Já fez seu devocional hoje? Aproveite e marque um amigo para fazer junto com você! Confira:  Recentemente, estive num lugar que eu havia visto inúmeras vezes na televisão e em filmes: Hollywood, Califórnia. Lá, nas colinas de Los Angeles, o enorme letreiro se destacava orgulhoso na famosa paisagem que eu via da janela do hotel. E aí percebi algo mais: abaixo dele havia uma cruz proeminente que eu nunca tinha visto em filme nenhum. Assim que saí do meu hotel, alguns estudantes de uma igreja local começaram a me falar de Jesus. Às vezes pensamos que Hollywood é o epicentro do mundanismo, em enorme contraste com o reino de Deus. Porém, Jesus claramente estava agindo lá, surpreendendo-me com a Sua presença. Os fariseus surpreendiam-se constantemente com os locais onde Jesus aparecia. Ele não se juntava às pessoas que os fariseus esperavam que se ajuntasse. Pelo contrário, lemos em Marcos 2 que Ele convivia com “cobradores de impostos e outros pecadores” (v.15), pessoas cujo testemunho parecia gritar: “Impuro!”. Mas lá estava Jesus, junto daqueles que mais precisavam dele (vv.16-17). Mais de 2000 anos depois, Jesus continua a semear a Sua mensagem de esperança e salvação em lugares inesperados, entre as pessoas mais inesperadas. E Ele nos convoca e capacita para participar desta missão.  Por: ADAM R. HOLZ 

Atenção (disclaimer): Os dados aqui apresentados representam minha opinião pessoal.Não são de forma alguma indicações de compra ou venda de ativos no mercado financeiro.Seleção das partes mais interessantes das Lives de segunda.Live 324 - Visão do Estrategistahttps://youtube.com/live/_HcKEQAqt7I

Atenção (disclaimer): Os dados aqui apresentados representam minha opinião pessoal.Não são de forma alguma indicações de compra ou venda de ativos no mercado financeiro.Seleção das partes mais interessantes das Lives de segunda.Live 324 - Visão do Estrategistahttps://youtube.com/live/_HcKEQAqt7I

Atenção (disclaimer): Os dados aqui apresentados representam minha opinião pessoal.Não são de forma alguma indicações de compra ou venda de ativos no mercado financeiro.Live para responder perguntas e tirar dúvidas sobre o mercado financeiro e temas relacionados.Sobre doações para o canal #INVESTIRCOMSIM 18/02/25https://youtube.com/shorts/NZLctbFyx6M

Confira nesta edição do JR 24 Horas: O ministro Alexandre de Moraes, do Supremo Tribunal Federal, determinou a prisão dos três condenados pela tentativa de explosão de um caminhão-tanque perto do aeroporto de Brasília, em 2022. Alexandre de Moraes entendeu que a tentativa deexplosão está ligada aos atos do 8 de janeiro de 2023. George Washington de Oliveira, Alan Diego dos Santos Rodrigues e Wellington Macedo de Souza ficarão presos por tempo indeterminado. Os três já haviam sido condenados e cumpriam a pena em regime semiaberto. E ainda: A Agência Nacional de Energia Elétrica decidiu manter a bandeira vermelha patamar 1 para o mês de julho na conta de luz.

Actress Jessica Lowe (The Righteous Gemstones, Minx, Wrecked) joins Nicole to share the romantic saga of falling in love on a Second City cruise ship. On the ship, she met a British bassist who became her cruise ship boyfriend - whom she later realized wasn't as smart as she thought his accent sounded (he tried to dry his pants on a ceiling fan and designed a nightmare demon tattoo for himself).Jessica recalls dating a Dutch chef with a penis that was “too much!” and recounts what might be the most romantic first date ever told on the podcast. She reflects on the men who surprised her, disappointed her, and the slow work of building a relationship that actually lasted.Plus, Jessica and Nicole reminisce about the chaos of filming Curse Friends when everyone tested positive for COVID - and Nicole opens up about sobbing in a makeup chair over a man who simply wasn't worth it.Watch this episode on our YouTube channel at https://www.youtube.com/@WhyWontYouDateMePodcastSupport this podcast and get discounts by checking out our sponsors:» OneSkin: OneSkin is redefining the aging process with their proprietary OS-01 peptide. Get 15% off OneSkin with the code DATEME at https://www.oneskin.co/ #oneskinpod» SquareSpace: Head to squarespace.com/DATEME to save 10% off your first purchase of a website or domain using code DATEME.» Booking.com: Book now at Booking.com!» Smalls: Give your cat the food they deserve. For a limited time only, get 60% off your first order PLUS free shipping when you head to Smalls.com and use code DATEME.View all of our sponsors and discounts codes at wwydm.notion.site/sponsors.Follow:Tour Dates: linktr.ee/nicolebyerwastakenYouTube: @WhyWontYouDateMePodcastTikTok: @whywontyoudatemepod Instagram: @nicolebyerX: @nicolebyerNicole's book, #VERYFAT #VERYBRAVE: indiebound.org/book/9781524850746This is a Headgum podcast. Follow Headgum on Twitter, Instagram, and Tiktok. Advertise on Why Won't You Date Me? via Gumball.fm.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

31 Then the Jews, (because it was the parasceve,) that the bodies might not remain on the cross on the sabbath day, (for that was a great sabbath day,) besought Pilate that their legs might be broken, and that they might be taken away.Judaei ergo ( quoniam parasceve erat) ut non remanerent in cruce corpora sabbato ( erat enim magnus dies ille sabbati), rogaverunt Pilatum ut frangerentur eorum crura, et tollerentur. 32 The soldiers therefore came; and they broke the legs of the first, and of the other that was crucified with him.Venerunt ergo milites : et primi quidem fregerunt crura, et alterius, qui crucifixus est cum eo. 33 But after they were come to Jesus, when they saw that he was already dead, they did not break his legs.Ad Jesum autem cum venissent, ut viderunt eum jam mortuum, non fregerunt ejus crura, 34 But one of the soldiers with a spear opened his side, and immediately there came out blood and water.sed unus militum lancea latus ejus aperuit, et continuo exivit sanguis et aqua. 35 And he that saw it, hath given testimony, and his testimony is true. And he knoweth that he saith true; that you also may believe.Et qui vidit, testimonium perhibuit : et verum est testimonium ejus. Et ille scit quia vera dicit : ut et vos credatis. 36 For these things were done, that the scripture might be fulfilled: You shall not break a bone of him.Facta sunt enim haec ut Scriptura impleretur : Os non comminuetis ex eo. 37 And again another scripture saith: They shall look on him whom they pierced.Et iterum alia Scriptura dicit : Videbunt in quem transfixerunt.The Sacred Heart of our Lord is opened on the Cross by the soldier's lance to manifest to us His Love.

« Drame au lycée Boganda à Bangui : 29 morts : Touadéra décrète trois jours de deuil », titre Afrik.com qui parle d'un « drame d'une ampleur inédite », « une violente bousculade, survenue en pleine session du baccalauréat ». « A l'origine du chaos », explique Afrik.com, « l'explosion d'un transformateur électrique de la société nationale ENERCA, qui a semé la panique, parmi les candidats et le personnel éducatif (…) les élèves ont cru à une attaque ou à un danger imminent. Pris de panique, ils se sont précipités dans les couloirs, ce qui a déclenché une bousculade incontrôlable ». Corbeau News Centrafrique ne cache pas sa colère, à l'égard de la Société nationale d'Électricité, à laquelle il s'adresse en ces termes : « combien de temps faudra-t-il pour que vous cessiez de tuer les Centrafricains ? » Corbeau News Centrafrique accuse : « ce drame survenu en plein cœur de la capitale n'est, pas une exception. Il s'inscrit dans une longue série de négligences criminelles de la part d'Enerca, une entreprise censée fournir de l'électricité, mais qui sème la mort à chaque coin de rue ». Le journal en veut pour preuve cet accident survenu le 23 mai dernier, « lorsqu'un jeune vendeur d'œufs a été électrocuté en plein centre-ville de Bangui, foudroyé par une fuite de courant dans une flaque d'eau. » Catastrophe prévisible Corbeau News Centrafrique s'en prend aussi au ministre de l'Éducation nationale, qui a publié « un communiqué qui tente de calmer les esprits, mais ne fait qu'attiser la colère », estime le journal, « car le communiqué du ministère parle de « quelques cas de pertes en vies humaines ». « Comme s'il s'agissait, estime le journal, d'une statistique banale… C'est une insulte aux familles endeuillées ». « Des élèves ont perdu la vie, piétinés, électrocutés, dans la panique causée par l'explosion d'un transformateur, installé depuis des années sans maintenant adéquate, une bombe à retardement qu'ENERCA a laissé en place, en toute connaissance de cause », accuse encore Corbeau News Centrafrique. Intégrité territoriale À lire également dans la presse africaine, les commentaires sur l'accord de paix qui doit être signé ce vendredi à Washington, entre la RDC et le Rwanda. « RDC – Rwanda : un accord de paix pour conserver l'intégrité territoriale congolaise », titre l'Agence Congolaise de Presse, qui cite Osée Yandi, présenté comme un « analyste des questions politiques extérieures », selon lequel, « cet accord doit également permettre à la RDC, de se reconstituer en tant que force pour pouvoir dissuader tout ennemi qui adviendrait sur son terrain ». Jeune Afrique de son côté, se demande : « Quel est l'intérêt des Américains ? »  alors que « la nouvelle administration américaine se montre plutôt indifférente, voire hostile à l'égard du continent africain. ». Ce qui semble le plus évident, aux yeux de Jeune Afrique, c'est que « l'activité minière » intéresse au plus haut point l'administration américaine. « En sécurisant leur approvisionnement en minerais critiques, poursuit Jeune Afrique, les États-Unis concurrenceraient leur rival chinois, déjà bien implanté en RDC. » De manière plus anecdotique, il faut noter aussi que « Donald Trump est en quête d'une victoire diplomatique » qui, nous dit le site panafricain, « consacrerait son statut de faiseur de paix ». Prix Nobel Un statut que Félix Tshisekedi serait prêt à lui accorder ! Dans une interview exclusive à la journaliste américaine Hariana Veras Victoria, le président congolais, se déclare ainsi « prêt à voter pour Donald Trump au prix Nobel de la Paix, si ce dernier parvient à en finir avec la guerre injustement imposée à son pays par le Rwanda ». C'est ce que rapportent Objectif-Info.cd et le Journal de Kinshasa, selon lequel Tshisekedi ne « cache pas son admiration pour le président américain ». 

Tanya 1 Tamuz Cap 10 Parte 1 -Os atributos divinos são chamados de luzes,como raio solares anulados

Os dois homens considerados culpados pelo homicídio de um adolescente indígena, que ocorreu em outubro de 2022 nos subúrbios a leste de Perth, serão condenados hoje, 27 de junho. Ministros da Educação das várias regiões da Austrália reúnem esta sexta-feira, 27 de junho, em Adelaide, para discutir reformas no setor da educação pré-escolar. Estas e outras notícias em destaque, no noticiário de hoje.

FreeBSD version 14.3 is available, Reliable ZFS Storage on Commodity Hardware, My website is ugly because I made it, Semi distributed filesystems with ZFS and Sanoid, April 2025 Laptop Support and Usability Project Update, UDP sockets instead of BPF in dhcpd(8), and more NOTES This episode of BSDNow is brought to you by Tarsnap (https://www.tarsnap.com/bsdnow) and the BSDNow Patreon (https://www.patreon.com/bsdnow) Headlines FreeBSD 14.3 released (https://www.freebsd.org/releases/14.3R/announce/) Reliable ZFS Storage on Commodity Hardware (https://klarasystems.com/articles/cost-efficient-storage-commodity-hardware/) News Roundup My website is ugly because I made it (https://goodinternetmagazine.com/my-website-is-ugly-because-i-made-it/) Semi distributed filesystems with ZFS and Sanoid (https://anil.recoil.org/notes/syncoid-sanoid-zfs) April 2025 Laptop Support and Usability Project Update (https://freebsdfoundation.org/blog/april-2025-laptop-support-and-usability-project-update/) dhcpd(8): use UDP sockets instead of BPF (https://undeadly.org/cgi?action=article;sid=20250613111800) Tarsnap This weeks episode of BSDNow was sponsored by our friends at Tarsnap, the only secure online backup you can trust your data to. Even paranoids need backups. Feedback/Questions No feedback this week. Send more... Send questions, comments, show ideas/topics, or stories you want mentioned on the show to feedback@bsdnow.tv (mailto:feedback@bsdnow.tv) Join us and other BSD Fans in our BSD Now Telegram channel (https://t.me/bsdnow)

O UOL revelou que, neste ano, o Ministério da Saúde está liberando um "extra" para parlamentares da base aliada, que pode chegar a R$8 bilhões.  Os ministérios têm mais controle sobre essas verbas do que tem sobre emendas parlamentares. Mas também não há publicidade sobre quem são os "padrinhos".  Neste episódio do UOL Prime, José Roberto de Toledo conversa com Natália Portinari sobre como funciona esse instrumento de negociação política. #uolprime #PodcastUOLPrime

Durante o julgamento no STF sobre a responsabilização de redes sociais, a ministra Cármen Lúcia falou, ao proferir seu voto, em “213 milhões de pequenos tiranos” para justificar censura. O placar no Supremo ficou em 8 a 3 contra as big techs. Os votos vencidos foram os de André Mendonça, Luiz Edson Fachin e Kassio Nunes Marques. Felipe Moura Brasil e Ricardo Kertzman comentam:Papo Antagonista é o programa que explica e debate os principais acontecimentos do   dia com análises críticas e aprofundadas sobre a política brasileira e seus bastidores.     Apresentado por Felipe Moura Brasil, o programa traz contexto e opinião sobre os temas mais quentes da atualidade.     Com foco em jornalismo, eleições e debate, é um espaço essencial para quem busca informação de qualidade.     Ao vivo de segunda a sexta-feira às 18h.    Apoie o jornalismo Vigilante: 10% de desconto para audiência do Papo Antagonista  https://bit.ly/papoantagonista  Siga O Antagonista no X:  https://x.com/o_antagonista   Acompanhe O Antagonista no canal do WhatsApp. Boletins diários, conteúdos exclusivos em vídeo e muito mais.  https://whatsapp.com/channel/0029Va2SurQHLHQbI5yJN344  Leia mais em www.oantagonista.com.br | www.crusoe.com.br 

O deputado federal Kim Kataguiri e o deputado estadual Guto Zacarias – ambos da União Brasil – pediram ao Ministério Público Federal (MPF) uma investigação sobre uma possível prática de improbidade administrativa por parte da deputada federal Erika Hilton (PSOL-SP).A iniciativa foi motivada pelo reembolso de 24 mil reais solicitado por Erika Hilton à Câmara, referente a uma cirurgia na região do nariz. Segundo declarações públicas da parlamentar, o procedimento teve natureza funcional e estética — sendo que a parte estética teria sido custeada por ela.Os parlamentares, no entanto, questionam a realização conjunta dos procedimentos — médico e estético — em um mesmo ato cirúrgico, o que levanta dúvidas sobre o real fracionamento dos custos e o efetivo uso de dinheiro público. Felipe Moura Brasil e Ricardo Kertzman comentam:Papo Antagonista é o programa que explica e debate os principais acontecimentos do   dia com análises críticas e aprofundadas sobre a política brasileira e seus bastidores.     Apresentado por Felipe Moura Brasil, o programa traz contexto e opinião sobre os temas mais quentes da atualidade.     Com foco em jornalismo, eleições e debate, é um espaço essencial para quem busca informação de qualidade.     Ao vivo de segunda a sexta-feira às 18h.    Apoie o jornalismo Vigilante: 10% de desconto para audiência do Papo Antagonista  https://bit.ly/papoantagonista  Siga O Antagonista no X:  https://x.com/o_antagonista   Acompanhe O Antagonista no canal do WhatsApp. Boletins diários, conteúdos exclusivos em vídeo e muito mais.  https://whatsapp.com/channel/0029Va2SurQHLHQbI5yJN344  Leia mais em www.oantagonista.com.br | www.crusoe.com.br 

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News.  I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode.  Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC.   Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings.  So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease.  So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting.  So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting.  So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response.  So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma.  So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025.  So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence.  So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj.  Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer.  So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response.  These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months.  Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup.  So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj.  Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial.  A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion.  So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance.  So, thank you, Jeanny, for joining me today and sharing your insights.  And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Neeraj Agarwal     @neerajaiims     Dr. Jeanny Aragon-Ching   Follow ASCO on social media:       @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn       Disclosures:   Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas  Dr. Jeanny Aragon-Ching:   Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono   Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,    Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics

Os aliados acordaram em aumentar as despesas com defesa para 5% do PIB. A cimeira de Haia constitui um novo marco histórico para a organização. E Portugal vai cumprir? Madalena Moreira, jornalista, é a convidada.See omnystudio.com/listener for privacy information.

¿Qué ocurre cuando un cuadro te observa desde la pared? En este episodio de DÍAS EXTRAÑOS, Xavi Villanueva nos trae 'El Cuadro', un relato de Arturo Panero González que convertirá tu dormitorio en una pesadilla. Una historia que comienza con un niño fascinado por una pintura grotesca y evoluciona hacia algo que jamás podrás imaginar. Obsesión, locura y colores que sangran... literalmente. ADVERTENCIA: Después de escucharlo, mirarás cualquier cuadro de forma muy diferente. ¿Te atreves a descubrir qué habita realmente en los lienzos? Una experiencia auditiva que se quedará grabada en tu retina. Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

No sé cómo hemos llegado a 600 programas, ni cómo hemos llegado vivos. Ha sido una temporada emocionante en la que os hemos sentido desde el principio. Os regalamos este especial con toda vuestra banda de idiotas favorita, incluyendo alguna sorpresa que os va a gustar. Nos vemos en septiembre, no. O quizás en julio.

No sé cómo hemos llegado a 600 programas, ni cómo hemos llegado vivos. Ha sido una temporada emocionante en la que os hemos sentido desde el principio. Os regalamos este especial con toda vuestra banda de idiotas favorita, incluyendo alguna sorpresa que os va a gustar. Nos vemos en septiembre, no. O quizás en julio.

Muchos más recursos para tu vida de fe (Santo Rosario, Oración, etc.) en nuestra web https://sercreyente.com________________Viernes, 27 de junio de 2025 (Sagrado Corazón de Jesús)Evangelio del día y reflexión... ¡Deja que la Palabra del Señor transforme tu vida! Texto íntegro del Evangelio y de la Reflexión en https://sercreyente.com/sagrado-corazon-de-jesus-ciclo-c/[Lucas 15, 3-7] En aquel tiempo dijo Jesús a los fariseos y escribas esta parábola: «¿Quién de vosotros que tiene cien ovejas y pierde una de ellas, no deja las noventa y nueve en el desierto y va tras la descarriada, hasta que la encuentra? Y, cuando la encuentra, se la carga sobre los hombros, muy contento; y, al llegar a casa, reúne a los amigos y a los vecinos, y les dice: “¡Alegraos conmigo!, he encontrado la oveja que se me había perdido”. Os digo que así también habrá más alegría en el cielo por un solo pecador que se convierta que por noventa y nueve justos que no necesitan convertirse.________________Descárgate la app de SerCreyente en https://sercreyente.com/app/¿Conoces nuestra Oración Online? Más información en: https://sercreyente.com/oracion¿Quieres recibir cada día el Evangelio en tu whatsapp? Alta en: www.sercreyente.com/whatsappTambién puedes hacer tu donativo en https://sercreyente.com/ayudanos/Contacto: info@sercreyente.com

Luke Cook is an actor, comedian, wellness enthusiast, and creator best known for his roles in Chilling Adventures of Sabrina and the new series Good Cop/Bad Cop, as well as co-founder of the clean-label protein company Shakewell.15 Daily Steps to Lose Weight and Prevent Disease PDF: https://bit.ly/46XTn8f - Get my FREE eBook now!Subscribe to The Genius Life on YouTube! - http://youtube.com/maxlugavereWatch my new documentary Little Empty Boxes - http://littleemptyboxes.comThis episode is proudly sponsored by:AG1 is my favorite multivitamin. Enjoy a free 1 year supply of vitamin D and 5 free AG1 travel packs with your first purchase. All you have to do is visit drinkag1.com/GENIUS.Puori provides IFOS-certified, high potency fish oil to satisfy all of your omega-3 needs! Plus a ton of other high quality, rigorously tested supplements. Visit ⁠Puori.com/MAX⁠ and use promo code MAX to get 20% off site-wide.First Light Farms produces beautiful, delicious, grass-fed meats on their pristine New Zealand farm, and ships them straight to your doorstep. Visit http://firstlight.farm and use code MAX15 for 15% off.Shopify makes it easy to accept payments, manage orders, and build relationships with customers (cha-ching!). Get everything you need to sell in person and online at http://shopify.com/genius and get a one-dollar-per-month trial period!OneSkin is a skincare company for minimalists utilizing their revolutionary OS-01 peptide which can reverse signs of skin aging according to their research. Visit http://oneskin.co/max and use code MAX for 15% off.Pique makes quadruple toxin-screened, cold extracted, and uber-delicious matcha for an all-day energy boost without the jitters! Head to http://piquelife.com/genius for up to 15% off.

It's easy to assume that food affects everyone the same way. But when my wife Kathy and I wore continuous glucose monitors for two weeks, we learned just how different our responses actually are.  For example, a bowl of curry or a few slices of sourdough bread would send her blood sugar soaring while barely impacting mine, and vice versa.  We weren't just tracking data: we were uncovering real-time insight into how our individual metabolisms, hormones, stress, and even muscle mass shape our daily health outcomes. The experiment revealed a few surprising truths. For Kathy, sourdough and rice were consistent triggers, even when paired with protein and fat. Her blood sugar spiked above 200 mg/dL and stayed elevated for hours — a clear sign that not all “healthy carbs” are created equal.  For me, the biggest spike didn't come from food at all. It came from intense physical activity — proof that exercise-induced glucose changes are an entirely different metabolic story than post-meal crashes. The differences went deeper than food. Kathy's menstrual cycle impacted her insulin sensitivity, and my lean muscle mass gave me an edge when it came to buffering glucose. We also saw how stress, sleep and cold plunging could subtly (and sometimes dramatically) influence blood sugar trends, even in the absence of a single bite of food. None of this was about fearmongering over carbs or obsessing over numbers. Wearing a CGM isn't a lifestyle; it's a short-term lens into how your body actually works. And once you connect the data to how you feel — sluggish after rice, energized after steak, restless after a late-night spike — that's when you unlock real change. If you're serious about optimizing your health, I highly recommend trying a CGM for just a few weeks. Learn what your body thrives on. Understand what derails you. And then build your habits accordingly. Because personalized data beats generic diet advice every time. Learn more: Try the Levels Health app and get 2 months free when you sign up for an annual membership with my affiliate link: levels.link/MK  How Continuous Glucose Monitoring Can Improve Your Health and Fitness:https://michaelkummer.com/continuous-glucose-monitoring/ 44: Why You Should Wear a Continuous Glucose Monitor (CGM): https://www.primalshiftpodcast.com/44-why-you-should-wear-a-continuous-glucose-monitor-cgm/ Thank you to this episode's sponsor, OneSkin! OneSkin's lineup of topical skin health products leverage the power of the company's proprietary OS-01 peptide to remove dead skin cells, improve collagen production, increase skin hydration and more.  Check out my before and after photos in my OneSkin review: https://michaelkummer.com/health/oneskin-review/  Get 15% off with my discount code MKUMMER: https://michaelkummer.com/go/oneskinshop  In this episode: 00:00 - Introduction: Blood Sugar Spikes 00:48 - Experiment Setup and Initial Findings 02:15 - Sourdough Experiment: A Surprising Spike 04:53 - Top Blood Sugar Triggers 07:17 - Personal Blood Sugar Responses 10:31 - Factors Influencing Blood Sugar 13:41 - Managing Blood Sugar Spikes 21:53 - Conclusion: Is a CGM Worth It? Find me on social media for more health and wellness content: Website: https://michaelkummer.com/ YouTube: https://www.youtube.com/@MichaelKummer Instagram: https://www.instagram.com/primalshiftpodcast/ Pinterest: https://www.pinterest.com/michaelkummer/ Twitter/X: https://twitter.com/mkummer82 Facebook: https://www.facebook.com/realmichaelkummer/ [Medical Disclaimer] The information shared on this video is for educational purposes only, is not a substitute for the advice of medical doctors or registered dietitians (which I am not) and should not be used to prevent, diagnose, or treat any condition. Consult with a physician before starting a fitness regimen, adding supplements to your diet, or making other changes that may affect your medications, treatment plan, or overall health. [Affiliate Disclaimer] I earn affiliate commissions from some of the brands and products I review on this channel. While that doesn't change my editorial integrity, it helps make this channel happen. If you'd like to support me, please use my affiliate links or discount code. #LevelsHealth #CGM 

Tillbakablickarna och ny-reflektionernahaglar i denna andra del av vårt Jubiléum:Betyder Musiken ingenting för vissa? ”It's just a song” ?Vad har Chris lärt sig på kort tid?Är att spela på gatan en HÅRD men nyttig skola?Skäller inte Chris ut folk längre, som inte sköter sig på repet?Har vi löst frågan om hur folk diggar sin musik med huvudet,Framåt eller bakåt?OS-invigningen tar vi också hand om.Vi strävar framåt och utlovar nytt och intressant innehålloch vad vi strävar efter i säsong 6 som står för dörren.TACK alla som lyssnar, vi är helt enkelt oerhört tacksammaför denna möjlighet att sprida musikglädje till er.Mycket välkomna!Vill du ha din låt uppspelad direktmed tillhörande analys.Maila oss låtlänk + info om projektet till: Musiksnacket@iwm.seLänk till Spellista:https://open.spotify.com/playlist/25dSufz7mpKXI0vbMclpgz?si=77c7b74518db43fd#recension #analyser #musik #analys #spotify #Podcast #podd #musiksnacket #Artist #Musiker #scen #studio #AI

Os convidados do programa Pânico dessa quarta-feira (25) são Prof. Noslen Borges e ⁠Fernando De Borthole.Professor Noslen BorgesNoslen Borges é um dos maiores comunicadores da área educacional no Brasil. Criador do maior canal de ensino de língua portuguesa do mundo e do maior canal de educação do país, acumula mais de 5 milhões de inscritos e 400 milhões de visualizações no YouTube. Formado em Letras, com mais de 20 anos de atuação em sala de aula, Noslen se reinventou nas redes sociais, onde passou a ensinar de forma moderna, criativa e acessível. Hoje, leva essa mesma energia para os palcos: suas palestras e aulões combinam conteúdo, humor e inspiração, sempre com uma linguagem atual e próxima dos estudantes.Fenômeno no YouTube, o Prof. Noslen Borges lança o primeiro livro Português para não pagar mico pelo Grupo Editorial Citadel. Na obra, o autor transmite a didática leve e bem-humorada dos vídeos para as páginas, com o dinamismo da comunicação descontraída dos jovens e das redes sociais.Com QR Codes que direcionam os leitores para videoaulas exclusivas, Português para não pagar mico é destinado especialmente a estudantes, concurseiros e profissionais que desejam se comunicar com mais precisão. A comunicação objetiva, os exemplos corriqueiros e o estilo descontraído característico do Prof. Noslen Borges tornam o aprendizado mais eficaz, mesmo para quem carrega bloqueios antigos com a gramática tradicional. Mais do que ensinar regras, ele mostra a importância de enxergar a língua portuguesa como uma aliada na busca de oportunidades.Redes Sociais:Instagram: https://www.instagram.com/professornoslen/YouTube: https://www.youtube.com/@ProfessorNoslenFernando De BortholeCom uma carreira que decola há mais de duas décadas, o aviador, empreendedor e produtor audiovisual Fernando De Borthole consolidou-se como uma das principais vozes da aviação no Brasil e no mundo. Reconhecido por sua capacidade única de unir expertise técnica com uma comunicação acessível e envolvente, Fernando transformou a complexidade do setor aeronáutico em conteúdo fascinante para milhões de espectadores e seguidores.Desde a criação do aclamado programa "Aero – Por Trás da Aviação", que se tornou um fenômeno digital e multiplataformas, Borthole tem levado o público a uma jornada inédita pelos bastidores da aviação. Com mais de 20 anos de experiência como piloto, sua formação em Aviação Civil pela Universidade Anhembi Morumbi (2004) e especialização em produção audiovisual na Vancouver Film School, no Canadá, fundamentaram a base de seu trabalho inovador.Além do sucesso estrondoso de "Aero – Por Trás da Aviação", que lhe rendeu o Prêmio ABEAR de Jornalismo em 2015 e o Prêmio iBest 2024 na categoria "Influenciador Automotivo e de Transportes", Fernando De Borthole é sócio da Escola Superior do Ar (EAR), a única faculdade 100% focada em educação aeronáutica no país. Ele também é parceiro do Projeto Transplantar, iniciativa que viabiliza o uso de aeronaves privadas para o transporte urgente de órgãos para transplante, demonstrando seu compromisso com causas sociais de grande impacto. Em 2024, foi agraciado com a Medalha Santos Dumont, em reconhecimento à sua notável contribuição para a divulgação da cultura aeronáutica.Sua presença constante na mídia, incluindo participações em programas de TV como Jornal Nacional, Encontro com Patrícia Poeta, CNN Brasil, e em podcasts populares como Flow Podcast e Ticaracaticast, solidifica sua posição como um comunicador respeitado e uma autoridade incontestável no setor.Fernando De Borthole continua a expandir fronteiras, com projetos que transcendem o ambiente digital e contribuem significativamente para a educação e a conscientização sobre a aviação, sempre com o objetivo de inspirar novas gerações e fortalecer a imagem de um dos setores mais vitais da economia global.Redes Sociais:Instagram: https://www.instagram.com/programaaero/Youtube: https://www.youtube.com/@aeroportrasdaaviacao

Episodio 324. Hay una gran cantidad de teoremas divertidamente arbitrarios que dicen que mi baticinturón pila, en términos de lo que jala, me deja amarrado como un perrito a la pared con una cola USB C que me la pongo en la espalda y está bien. La odio y está ahí desde hace siempre, pero me da miedo quitarla y que se apague la luz.

Os dois países cantaram vitória na guerra, mas solução definitiva ocorreu somente por intermédio dos Estados UnidosMeio-Dia em Brasília traz as principais notícias e análises da política nacional direto   de Brasília.     Com apresentação de José Inácio Pilar e Wilson Lima, o programa aborda os temas mais quentes do cenário político e econômico do Brasil.     Com um olhar atento sobre política, notícias e economia, mantém o público bem informado.   Transmissão ao vivo de segunda a sexta-feira às 12h.   Apoie o jornalismo Vigilante: 10% de desconto para audiência do Meio-Dia em Brasília   https://bit.ly/meiodiaoa   Siga O Antagonista no X:  https://x.com/o_antagonista   Acompanhe O Antagonista no canal do WhatsApp. Boletins diários, conteúdos exclusivos em vídeo e muito mais.  https://whatsapp.com/channel/0029Va2SurQHLHQbI5yJN344  Leia mais em www.oantagonista.com.br | www.crusoe.com.br 

Os petistas Lindbergh Farias, Gleisi Hoffmann e Fernando Haddad voltaram a defender o decretodo governo que aumenta o IOF, em meio à movimentação no Congresso contra a medida.Lindbergh e Haddad recorreram ao discurso da luta de classes, enquanto Gleisi afirmou que  a derrubada do decreto pode “prejudicar” a execução de emendas.Felipe Moura Brasil, Dennys Xavier e Ricardo Kertzman comentam:Papo Antagonista é o programa que explica e debate os principais acontecimentos do   dia com análises críticas e aprofundadas sobre a política brasileira e seus bastidores.     Apresentado por Felipe Moura Brasil, o programa traz contexto e opinião sobre os temas mais quentes da atualidade.     Com foco em jornalismo, eleições e debate, é um espaço essencial para quem busca informação de qualidade.     Ao vivo de segunda a sexta-feira às 18h.    Apoie o jornalismo Vigilante: 10% de desconto para audiência do Papo Antagonista  https://bit.ly/papoantagonista  Siga O Antagonista no X:  https://x.com/o_antagonista   Acompanhe O Antagonista no canal do WhatsApp. Boletins diários, conteúdos exclusivos em vídeo e muito mais.  https://whatsapp.com/channel/0029Va2SurQHLHQbI5yJN344  Leia mais em www.oantagonista.com.br | www.crusoe.com.br 

Sunscreen isn't optional—it's your #1 anti-aging secret. But with so many choices out there, how do you know which SPF actually works and feels good on your skin? In this special summer edition, I'm breaking down my top esthetician-approved sunscreens for 2025—featuring clean, effective, and glow-giving options for every skin type and lifestyle. From tinted serums to caffeinated creams and mineral formulas that disappear into your skin, I've got you covered (literally). Whether you're hitting the beach, running errands, or just trying to simplify your morning routine, this episode will help you find your perfect SPF match—without the guesswork. Your future skin will thank you. Let's dive in! XX, Lindsey Next Steps: Book a ONE on ONE Skincare Routine coaching call with me to get you Radiant skin!  LISTEN TO EXCLUSIVE PODCAST CONTENT and Download our FREE Esthetician led Skincare app: Apple IOS  Here OR Google Play Here Download my Free 7 Day Skincare Guide: Here If you liked this episode, you will also like this one : Discover Your Skin type: HERE Favorite Skincare Products HERE Pipette Minderal SPFEWG Verified!! BABO BOTANICALS | Tinted Face Mineral Sunscreen Stick SPF 50 - Fragrance Free The Skinny Confidential Caffeinated Mineral Sunscreen ONESKIN | Os-01 Shield Protect + Repair SPF 30+ Mychelle Light 3-In-1 Super Serum Beauty By Earth Self Tanner - Usa Made With Natural & Organic Ingredients Babo Botanicals Super Shield SPF 50 Stick Sunscreen - 70% Organic Ingredients Babo Botanicals Sheer Zinc Continuous Sunscreen Spray SPF30 ONESKIN | Os-01 Shield Protect + Repair SPF 30+ ONESKIN | Triple Power Os-01 Body SPF Babo Botanicals Daily Sheer Mineral Sunscreen Fluid SPF50 - Natural Zinc Oxide  KORA ORGANICS | Silky Sun Drops Organic Sunscreen Serum With SPF 30 Babo Botanicals Daily Sheer Tinted Mineral Sunscreen Fluid SPF50 - Natural Zinc Oxide Ava Isa Sun-È-Serum Drops SPF 35  Sun Cream SPF 30 Sun Stick SPF 25 Sun Lip Balm SPF 15 Os-01 Lip SPF Connect with me:  @lindseyrholder and @spaskinandbeauty  Leave a review and get instant access to my  48 Hour Skincare Makeover Guide: HERE Listen to related episodes: Dr. Trevor Cates on Hormonal imbalances and their effects on skin health, including acne, premature aging, and inflammation The Morning Skin Protocol That Changes Everything (From Lymph to Light) Skincare in a Hurry: Live Coaching a Busy Mom with Oily Skin & Dark Circles  

Randonáutica ha vuelto y nos ha traído nuevos casos, cada cual más terrorífico que el anterior. Os recomendamos no solo escuchar el capítulo, sino verlo también en el videopodcast que tenéis en Spotify o nuestro canal de Youtube. ¿Te atreverías a utilizar esta aplicación? ¡No te olvides de hacerte mecenas para tener además UN CAPÍTULO EXTRA cada semana! https://open.spotify.com/show/0azaM9tNLAiMKrFK6ZMlS1?si=e3d6fdb722c14844 Recuerda que puedes ver el videopodcast de este capítulo en nuestro canal de Youtube  https://www.youtube.com/@Terrores_TRN Ya a la venta el libro de Terrores Nocturnos “La españa Misteriosa”, en el que recopilamos los mejores casos paranormales, crímenes y lugares embrujados de nuestro país  https://bit.ly/3EkjU2u  Síguenos en nuestras redes sociales y escríbenos a nuestro correo: Instagram: @terroresnocturnos.trn Tiktok: @terroresnocturnos.trn Youtube: Terrores_TRN Twitter: @Terrores_TRN Twitch: terrores_trn Instagram Emma Entrena: @emma.e_trn Instagram Silvia Ortiz: @sil_trn Facebook: Terrores Nocturnos Correo: terroresnocturnosradio@gmail.com Presentado por Emma Entrena y Silvia Ortiz, producido por Yes We Cast e ilustrado por The Gray (@danionlybars) Learn more about your ad choices. Visit megaphone.fm/adchoices

We're finally digging into “Voodoo” - D'Angelo's Grammy-winning album that changed the sound of R&B, soul, and hip-hop forever. And the album a young Adam Maness had on repeat, seriously influencing his playing as well as countless musicians since.With Questlove's “Dilla-drag” drumming, Pino Palladino's funky bass lines, Roy Hargrove's jazzy horn arrangements, and Charlie Hunter's chicken-picking guitar, Voodoo is packed with the kind of cross-genre musicality that makes jazz musicians lose their minds.Twenty-five years later, Voodoo still grooves harder, hits deeper, and sounds more human than many albums of its generation.In this episode, you'll hear:What makes D'Angelo's groove so unique (and hard to imitate)Isolated tracks, rare demos, and interviews with the artistsHow “Spanish Joint” came together in a single takeWhether “Feel Like Makin' Love” tops the Roberta Flack originalAnd whether “Voodoo” is even an R&B album at allABOUT OPEN STUDIO------------------------------------------------------------------------------------------------------------------------------------------------------------As the premier online jazz education platform, with an ever-expanding course library and 20,000+ members, Open Studio (OS) has everything you need to excel and thrive on your jazz journey.Featuring everything from beginner to advanced lessons, engaging courses from A-list instructors, step-by-step curriculum, real-time classes and a thriving and incredibly supportive community, OS is the perfect platform to level up your jazz playing, whether you're a total beginner, or an advanced pro-level improvisor.

O Impacto da IA Generativa no Presente e Futuro dos DadosPrepare-se para uma conversa de altíssimo nível sobre como a Inteligência Artificial Generativa está transformando o mundo dos dados, das empresas e das carreiras. Neste episódio, Luan Moreno recebe Eduardo Ordax, Líder de IA Generativa na AWS, e Mateus Oliveira para discutir, sem rodeios, os impactos reais da IA no mercado.O que você vai aprender neste episódio:Como a IA Generativa está mudando a forma como construímos pipelines, produtos e soluções de dados.Os principais desafios que empresas enfrentam ao implementar GenAI — e por que tecnologia não é mais o problema, mas sim pessoas e dados.O papel da Engenharia de Dados no mundo da IA e como ela se conecta com conceitos como LLMOps, Fine-Tuning, Prompt Engineering e Data-Centric AI.Por que o domínio dos fundamentos nunca foi tão importante para quem trabalha (ou quer trabalhar) com dados e IA.Reflexões sobre o futuro das carreiras em dados e IA — será que os engenheiros de dados, cientistas de dados e desenvolvedores serão substituídos ou terão um papel ainda mais relevante?As diferenças entre usar IA para brincar no ChatGPT e levar IA para resolver problemas de negócios no mundo real, em escala e em produção.Este é um papo sobre IA. É uma imersão completa sobre os desafios, as oportunidades e a visão de futuro para quem trabalha com dados, engenharia, machine learning e inteligência artificial. Luan Moreno = https://www.linkedin.com/in/luanmoreno/

TV writer Lauren Ashley Smith (A Black Lady Sketch Show, Smith Sisters Live) joins Nicole to talk about how she met her wife the old-fashioned way - through Time Out New York's Singles issue.Lauren reveals the strange public response to being a “bachelor” in a magazine, how her wife was one of the only white women working at BET, and the complications that came with planning an interracial lesbian wedding.She also recalls a bizarre school Valentine's Day test that matched students based on compatibility, and she and Nicole discuss who gets to keep the friends after a breakup. Plus, Nicole gets a magical hot massage and somehow walks away being fluent in Greek.And Lauren shares one big piece of dating advice: why straight people should try dating more like lesbians -letting go of the gender roles getting in the way.Watch this episode on our YouTube channel at https://www.youtube.com/@WhyWontYouDateMePodcastSupport this podcast and get discounts by checking out our sponsors:» OneSkin: OneSkin is redefining the aging process with their proprietary OS-01 peptide. Get 15% off OneSkin with the code DATEME at https://www.oneskin.co/ #oneskinpod» EarnIn: Make Any Day Payday! When you download the EarnIn app, type in Why Won't You Date Me under PODCAST when you sign up – it'll really help the show. » Booking.com: Book now at Booking.com!» Wayfair: Wayfair. Every Style, Every Home.View all of our sponsors and discounts codes at wwydm.notion.site/sponsors.Follow:Tour Dates: linktr.ee/nicolebyerwastakenYouTube: @WhyWontYouDateMePodcastTikTok: @whywontyoudatemepod Instagram: @nicolebyerX: @nicolebyerNicole's book, #VERYFAT #VERYBRAVE: indiebound.org/book/9781524850746This is a Headgum podcast. Follow Headgum on Twitter, Instagram, and Tiktok. Advertise on Why Won't You Date Me? via Gumball.fm.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.